Meeting
2020 ASCO Virtual Scientific Program
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
Authors
Mikhail Fedyanin
Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation
Mikhail Fedyanin , Alexey Tryakin , Alla Sergeevna Lisyanskaya , Ekaterina Solovyeva , Natalia Fadeeva , Oleg Gladkov , Vladimir Moiseyenko , Sergey V. Cheporov , Polina Shpigotskaya , Andrei Purmal , Langdon L. Miller , Andrey Leonov , Kristina Zakurdaeva , Katerina Gurova , Andrei Gudkov , Sergei Tjulandin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
847
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3607)
DOI
10.1200/JCO.2020.38.15_suppl.3607
Abstract #
3607
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.
First Author: John Sarantopoulos
Poster
2019 ASCO Annual Meeting
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.
First Author: Curtis Robert Chong
Poster
2023 ASCO Annual Meeting
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
First Author: Ryan C. Lynch
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal